(Total Views: 618)
Posted On: 10/14/2020 9:14:19 AM
Post# of 155566
“What if LL was in the pool and did not get picked?”
You can never discuss a scenario like this without considering NP as a major factor. He’s turned down the opportunity to combine leronlimab with another therapeutic in the past for a COVID19 trial (March/April timeframe). Given his history, there’s a small chance that NP denied an offer to participate in this trial or denied to participate in the ACTIV program all together. We’ll never know at this point, but NIH funded trials have so far enrolled quickly and get a good amount of attention. This trial will further cause enrollment issues for the leronlimab S/C trial as competition for patients increases.
You can never discuss a scenario like this without considering NP as a major factor. He’s turned down the opportunity to combine leronlimab with another therapeutic in the past for a COVID19 trial (March/April timeframe). Given his history, there’s a small chance that NP denied an offer to participate in this trial or denied to participate in the ACTIV program all together. We’ll never know at this point, but NIH funded trials have so far enrolled quickly and get a good amount of attention. This trial will further cause enrollment issues for the leronlimab S/C trial as competition for patients increases.
(3)
(0)
